DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment

Completed

Conditions: Arthritis, Psoriatic

Interventions: Drug: Apremilast

First Posted Date: 2019-02-04

Last Posted Date: 2024-06-05

Lead Sponsor: Amgen

Target Recruit Count: 119

Registration Number: NCT03828045

Locations: 🇪🇸
Universitaire Vaudoise*, Vigo, Spain
🇪🇸
H Univ Canarias, Tenerife, Canarias, Spain
🇪🇸
H Parc Tauli, Barcelona, Cataluña, Spain

and more 17 locations

A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH

Phase 3

Completed

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: ABP 959
Drug: Eculizumab

First Posted Date: 2019-01-28

Last Posted Date: 2023-05-23

Lead Sponsor: Amgen

Target Recruit Count: 42

Registration Number: NCT03818607

Locations: 🇮🇪
Saint James's Hospital, Dublin, Ireland
🇨🇿
Fakultní Nemocnice Ostrava, Ostrava-Poruba, Czechia
🇨🇿
Fakultní Nemocnice Brno, Brno, Jihormoravsky KRAJ, Czechia

and more 21 locations

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

Phase 1

Completed

Conditions: Systemic Sclerosis
Cutaneous Lupus Erythematosus
Polymyositis
Systemic Lupus Erythematosus
Sjogren's Syndrome
Dermatomyositis

Interventions: Drug: VIB7734
Drug: Placebo

First Posted Date: 2019-01-25

Last Posted Date: 2024-12-13

Lead Sponsor: Amgen

Target Recruit Count: 31

Registration Number: NCT03817424

Locations: 🇪🇸
Viela Bio Investigative Site, Sevilla, Spain

A Controlled Trial of Erenumab in Migraine Prevention

Phase 3

Completed

Conditions: Migraine

Interventions: Drug: Erenumab
Drug: Placebo

First Posted Date: 2019-01-23

Last Posted Date: 2024-02-21

Lead Sponsor: Amgen

Target Recruit Count: 261

Registration Number: NCT03812224

Locations: 🇯🇵
Research Site, Kai-shi, Yamanashi, Japan

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Phase 2

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: Tezepelumab
Other: Placebo

First Posted Date: 2019-01-18

Last Posted Date: 2022-03-10

Lead Sponsor: Amgen

Target Recruit Count: 251

Registration Number: NCT03809663

Locations: 🇺🇸
Clinical Science Institute, Santa Monica, California, United States
🇺🇸
J Woodson Dermatology and Associates, Henderson, Nevada, United States
🇭🇺
CRU Hungary Kft, Miskolc, Hungary

and more 83 locations

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Phase 1

Terminated

Conditions: Metastatic Castration-resistant Prostate Cancer
Prostate Cancer

Interventions: Drug: acapatamab
Drug: Cytochrome P450 (CYP) Cocktail
Drug: Pembrolizumab
Drug: Etanercept

First Posted Date: 2019-01-03

Last Posted Date: 2025-04-08

Lead Sponsor: Amgen

Target Recruit Count: 212

Registration Number: NCT03792841

Locations: 🇺🇸
City of Hope at Long Beach Elm, Long Beach, California, United States
🇺🇸
El Camino Hospital, Campbell, California, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States

and more 27 locations

A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis

Phase 4

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Apremilast

First Posted Date: 2018-12-20

Last Posted Date: 2025-02-21

Lead Sponsor: Amgen

Target Recruit Count: 123

Registration Number: NCT03783026

Locations: 🇺🇸
The Doctors of Saint John's Medical Group, Santa Monica, California, United States
🇧🇪
UZ Leuven, Leuven, Belgium
🇨🇭
Hopital Universitaire Genevois - Beau-Sejour Hospital, Geneve, Switzerland

and more 33 locations

Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis

Phase 3

Terminated

Conditions: Juvenile Rheumatoid Arthritis

Interventions: Drug: Etanercept
Drug: Placebo to Etanerceot
Drug: Methotrexate

First Posted Date: 2018-12-19

Last Posted Date: 2019-08-02

Lead Sponsor: Amgen

Target Recruit Count: 25

Registration Number: NCT03781375

Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

Phase 2

Completed

Conditions: Juvenile Rheumatoid Arthritis

Interventions: Drug: Etanercept
Drug: Placebo

First Posted Date: 2018-12-19

Last Posted Date: 2019-08-02

Lead Sponsor: Amgen

Target Recruit Count: 69

Registration Number: NCT03780959

An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Apremilast
Other: Placebo

First Posted Date: 2018-12-17

Last Posted Date: 2024-05-14

Lead Sponsor: Amgen

Target Recruit Count: 289

Registration Number: NCT03777436

Locations: 🇺🇸
Skin Care Physicians of Georgia, Macon, Georgia, United States
🇨🇦
Lynderm Research Inc, Markham, Ontario, Canada
🇺🇸
Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States

and more 49 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy